Ranbaxy launches Osovair capsules for Asthmatics

New Delhi, Mar 28 (UNI) Ranbaxy Laboratories Ltd today launched Osovair inhalation capsules, a combination of Formoterol and Ciclesonide drugs, in India for the treatment of Asthma.

''We are delighted to launch this unique product Osovair, the only combination of its type, recommended for use once-a-day,'' company Senior Vice President and Regional Director (Asia and CIS) Sanjeev I Dani said.

Osovair is available in Rheocaps in 160 mcg and 320 mcg capacities depending on the severity of patients.

Earlier in 2006, the Company had launched Osonide (Ciclesonide) Inhaler, a novel once-a day product in this segment. In May 2006, the company entered into an in-licensing agreement for the Indian domestic market, with the Netherlands based Pharma Company, Eurodrug Laboratories, for the asthma product Doxophylline sold under the brand name 'Synasma'.

India presently has an estimated 15-20 million asthmatic patients and the estimated prevalence rate in 5-11 year old children is between 10-15 per cent.

UNI